0.62

7.83% 0.045

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $0.62, with a volume of 81,453. It is up +7.83% in the last 24 hours and up +5.10% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$0.575

Open:

$0.58

24h Volume:

81,453

Relative Volume:

0.55

Market Cap:

$36.17M

Revenue:

$76.19M

Net Income/Loss:

$-1.61M

P/E Ratio:

62.00

EPS:

0.01

Net Cash Flow:

$28.98M

1W Performance:

-4.17%

1M Performance:

+5.10%

6M Performance:

-53.03%

1Y Performance:

-63.31%

1-Day Range:

$0.57

$0.6421

1-Week Range:

$0.57

$0.668

52-Week Range:

$0.5052

$1.72

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2025-03-19

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	0.62	36.17M	76.19M	-1.61M	28.98M	0.01
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

May 07, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World

May 07, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune

May 05, 2025

Spero Therapeutics Confirms Q1 Earnings Date: Latest Updates on Rare Disease and MDR Programs Coming May 13 - Stock Titan

May 05, 2025

Apr 30, 2025

Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 30, 2025

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz

Apr 28, 2025

New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus

Apr 28, 2025

Spero Therapeutics appoints new CEO and board nominee - Investing.com

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com

Apr 28, 2025

Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan

Apr 28, 2025

Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 12, 2025

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 07, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire

Apr 07, 2025

Apr 05, 2025

Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 02, 2025

Mar 29, 2025

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India

Mar 28, 2025